<DOC>
	<DOCNO>NCT02098551</DOCNO>
	<brief_summary>Aim study use major allergen 1 birch-tree pollen ( Bet v 1 , Betula verrucosa , synonymous Betula pendula ) , investigate contribution immunoglobulin E ( IgE ) - versus non-IgE-mediated mechanism chronic skin inflammation atopic dermatitis patient .</brief_summary>
	<brief_title>Skin Testing With Recombinant Bet v 1 Hypoallergenic Recombinant Bet v 1 Fragments</brief_title>
	<detailed_description>In study non-IgE-reactive recombinant Bet v 1 ( rBet v 1 ) fragment ( F1 : aa 1-74 ; F2 : aa 75-160 ) fully IgE-reactive recombinant Bet v 1 ( aa 1-160 ) use skin prick test atopy patch test birch pollen allergic patient birch pollen induce exacerbation atopic dermatitis . For control purpose birch pollen allergic patient without birch pollen-induced atopic eczema , person allergy birch non-allergic people test . The individual subject vivo skin prick atopy patch test rBet v 1 , rBet v 1 fragment 1 , rBet v 1 fragment 2 equimolar mix rBet v 1 fragment . In parallel , IgE reactivity , vitro T cell proliferation , cytokine production study . Those analysis help determine relevance IgE mediate mechanism chronic skin inflammation T cell proliferation AD patient . A stain surface marker chemokine receptor ( CCR4 ) + cutaneous lymphocyte antigen ( CLA ) + reportedly enrich inflamed skin allow investigate whether patient high number T lymphocytes express CCR4 CLA tend exhibit strong skin inflammation . Moreover , allergen-specific antibody T cell response analyze 6-8 week epicutaneous allergen application .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>1 . Age 18 75 year 2 . They available complete study 1 . Severe general malady 2 . Severe skin inflammation test area 3 . Risk noncontrollable general reaction 4 . Pregnancy breastfeed 5 . Autoimmune diseases , immunedefects include immunosuppression , immunecomplexinduced immunopathies 6 . Contraindication adrenaline 7 . Patients longterm treatment systemic corticosteroid immunosuppressive drug , tranquilizer psychoactive drug 8 . Positive IgE reaction hypoallergenic Bet v 1 derivative 9 . The subject currently participate another clinical study subject expose investigational noninvestigational drug . 10 . The subject risk noncompliance study procedures/restrictions</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>atopic dermatitis</keyword>
	<keyword>bet v 1</keyword>
	<keyword>bet v 1 fragment</keyword>
	<keyword>allergy</keyword>
</DOC>